Searched over 200M research papers
10 papers analyzed
These studies suggest losartan is not a calcium channel blocker but is often combined with calcium channel blockers like amlodipine for enhanced blood pressure control and other health benefits.
20 papers analyzed
Losartan is an angiotensin II receptor blocker (ARB) commonly used to manage hypertension. Calcium channel blockers (CCBs) like amlodipine are another class of antihypertensive agents. Combining these two types of medications can offer synergistic benefits in blood pressure control and other cardiovascular outcomes.
Research indicates that combining losartan with a calcium channel blocker like amlodipine is more effective in reducing blood pressure than combining losartan with diuretics. A study comparing losartan/amlodipine (L/A) and losartan/hydrochlorothiazide (L/H) found that the L/A combination significantly lowered both office diastolic blood pressure and 24-hour mean ambulatory systolic blood pressure after 20 weeks of treatment. This suggests a superior efficacy of the ARB/CCB combination in managing hypertension.
Blood pressure variability (BPV) is a critical factor in cardiovascular risk. A study comparing the effects of losartan combined with either amlodipine or hydrochlorothiazide found that the ARB/CCB combination was more effective in reducing 24-hour BPV. This reduction was independent of the overall blood pressure levels, highlighting the added benefit of combining losartan with a calcium channel blocker.
Hypertension can lead to left ventricular (LV) diastolic dysfunction. A study comparing losartan combined with either hydrochlorothiazide or amlodipine found that both combinations improved LV relaxation similarly. However, the losartan/hydrochlorothiazide combination showed a significant decrease in the ratio of early mitral inflow velocity to e' velocity and left atrial volume index, indicating improved diastolic function.
Losartan has shown significant renal protective effects, particularly in patients with chronic kidney disease (CKD) and hypertension. Studies have demonstrated that losartan reduces proteinuria more effectively than amlodipine, which is crucial for slowing the progression of renal disease. This effect was observed in both diabetic and non-diabetic nephropathy patients . Additionally, losartan was found to decrease urinary albumin excretion and improve renal hemodynamics, further supporting its renal protective benefits.
Losartan has been shown to improve insulin sensitivity and glucose homeostasis in patients with type 2 diabetes and nephropathy. A study comparing losartan and amlodipine found that losartan significantly reduced fasting blood glucose, HbA1c, and urinary protein levels. It also increased C-peptide concentrations and the insulin sensitivity index, indicating better glucose control.
Combining losartan with a calcium channel blocker like amlodipine offers significant benefits in managing hypertension, reducing blood pressure variability, and improving cardiovascular and renal outcomes. This combination is particularly effective in reducing proteinuria and enhancing insulin sensitivity, making it a valuable option for patients with hypertension and comorbid conditions like diabetes and CKD. The evidence supports the use of ARB/CCB combinations as a superior therapeutic strategy compared to ARB/diuretic combinations.
Most relevant research papers on this topic